Trial Profile
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Feb 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 16 Feb 2022 Planned primary completion date changed from 16 Dec 2021 to 16 Dec 2022.
- 18 Aug 2021 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.